63283-36-3

• 常用中文名：骨化二醇
• 常用英文名：Calcifediol
• CAS号：63283-36-3
• 分子式：C₂₇H₄₆O₃
• 分子量：418.65
• 相关类别： 原料药 维生素类与矿物质类药 维生素AD类药
• 发布时间：2018-02-20 08:00:00
• 更新时间：2024-01-02 15:46:50
• Calcifediol monohydrate 是维生素 D3 的主要循环代谢物, 是一种竞争性抑制剂,Ki 值为 3.9 μM。

名称

• 中文名: 25-羟基维生素D3
• 英文名: Vitamin D3 25-hydroxy monohydrate
• 中文别名: 骨化二醇,(5Z,7E)-9,10-开环胆甾-5,7,10(19)-三烯-3b,25-二醇一水合物; 骨化二醇
• 英文别名: MFCD00867077; 1H-Indene-1-pentanol, octahydro-4-[(2Z)-2-[(5S)-5-hydroxy-2-methylenecyclohexylidene]ethylidene]-α,α,ε,7a-tetramethyl-, (εR,1R,3aS,4E,7aR)-, hydrate (1:1); EINECS 242-990-9; Calcifediol hydrate; (3S,5Z,7E)-9,10-Secocholesta-5,7,10-triene-3,25-diol hydrate (1:1); Calcifediol (monohydrate); Calcifediol

物化性质

• 沸点: 529.2ºC at 760 mmHg
• 分子式: C₂₇H₄₆O₃
• 分子量: 418.65
• 闪点: 221.4ºC
• PSA: 40.46000
• LogP: 6.73390
• 外观性状: 褐色,细粉末
• 蒸汽压: 2.07E-13mmHg at 25°C
• 储存条件: −20°C

生物活性

• 描述: Calcifediol monohydrate 是维生素 D3 的主要循环代谢物, 是一种竞争性抑制剂,Ki 值为 3.9 μM。
• 相关类别:
  信号通路 >> 维生素 D 相关 >> VD/VDR
  研究领域 >> 代谢疾病
• 体外研究: 脂质体或乙醇溶液中的Calcifediol对来自假单胞菌感染的鼠上皮细胞的促炎细胞因子KC的释放没有影响。用Calcifediol脂质体治疗感染的人支气管16-HBE细胞导致细菌存活率显着降低[1]。
• 参考文献:

  [1]. Castoldi A, et al. Calcifediol-loaded liposomes for local treatment of pulmonary bacterial infections. Eur J Pharm Biopharm. 2016 Nov 22.

MSDS

SECTION 1: Identification of the substance/mixture and of the company/undertaking Product identifiers Product name: 25-Hydroxyvitamin D3 monohydrate REACH No.: A registration number is not available for this substance as the substance or its uses are exempted from registration, the annual tonnage does not require a registration or the registration is envisaged for a later registration deadline. CAS-No.: 63283-36-3 Relevant identified uses of the substance or mixture and uses advised against Identified uses: Laboratory chemicals, Manufacture of substances SECTION 2: Hazards identification Classification of the substance or mixture Classification according to Regulation (EC) No 1272/2008 Acute toxicity, Oral (Category 2), H300 Acute toxicity, Inhalation (Category 1), H330 Acute toxicity, Dermal (Category 2), H310 Specific target organ toxicity - repeated exposure, Oral (Category 1), H372 For the full text of the H-Statements mentioned in this Section, see Section 16. Classification according to EU Directives 67/548/EEC or 1999/45/EC T+ Very toxicR24/25, R26, R48/25 For the full text of the R-phrases mentioned in this Section, see Section 16. Label elements Labelling according Regulation (EC) No 1272/2008 Pictogram Signal wordDanger Hazard statement(s) H300Fatal if swallowed. H310Fatal in contact with skin. H330Fatal if inhaled. H372Causes damage to organs through prolonged or repeated exposure if swallowed. Precautionary statement(s) P260Do not breathe dust/ fume/ gas/ mist/ vapours/ spray. P264Wash hands thoroughly after handling. P280Wear protective gloves/ protective clothing. P284Wear respiratory protection. P301 + P310IF SWALLOWED: Immediately call a POISON CENTER or doctor/ physician. P302 + P350IF ON SKIN: Gently wash with plenty of soap and water. Supplemental Hazardnone Statements Other hazards Lachrymator. SECTION 3: Composition/information on ingredients Substances Synonyms: 25-Hydroxycholecalciferol Formula: C27H44O2 · H2O Molecular Weight: 418,65 g/mol CAS-No.: 63283-36-3 Hazardous ingredients according to Regulation (EC) No 1272/2008 ComponentClassificationConcentration 25-Hydroxyvitamin D3 monohydrate CAS-No.63283-36-3Acute Tox. 2; Acute Tox. 1;<= 100 % Acute Tox. 2; STOT RE 1; H300, H310, H330, H372 Hazardous ingredients according to Directive 1999/45/EC ComponentClassificationConcentration 25-Hydroxyvitamin D3 monohydrate CAS-No.63283-36-3T+, R24/25 - R26 - R48/25<= 100 % For the full text of the H-Statements and R-Phrases mentioned in this Section, see Section 16 SECTION 4: First aid measures Description of first aid measures General advice Consult a physician. Show this safety data sheet to the doctor in attendance. If inhaled If breathed in, move person into fresh air. If not breathing, give artificial respiration. Consult a physician. In case of skin contact Wash off with soap and plenty of water. Take victim immediately to hospital. Consult a physician. In case of eye contact Flush eyes with water as a precaution. If swallowed Never give anything by mouth to an unconscious person. Rinse mouth with water. Consult a physician. Most important symptoms and effects, both acute and delayed The most important known symptoms and effects are described in the labelling (see section 2.2) and/or in section 11 Indication of any immediate medical attention and special treatment needed no data available SECTION 5: Firefighting measures Extinguishing media Suitable extinguishing media Use water spray, alcohol-resistant foam, dry chemical or carbon dioxide. Special hazards arising from the substance or mixture Carbon oxides Advice for firefighters Wear self contained breathing apparatus for fire fighting if necessary. Further information no data available SECTION 6: Accidental release measures Personal precautions, protective equipment and emergency procedures Wear respiratory protection. Avoid dust formation. Avoid breathing vapours, mist or gas. Ensure adequate ventilation. Evacuate personnel to safe areas. Avoid breathing dust. For personal protection see section 8. Environmental precautions Prevent further leakage or spillage if safe to do so. Do not let product enter drains. Methods and materials for containment and cleaning up Pick up and arrange disposal without creating dust. Sweep up and shovel. Keep in suitable, closed containers for disposal. Reference to other sections For disposal see section 13. SECTION 7: Handling and storage Precautions for safe handling Avoid contact with skin and eyes. Avoid formation of dust and aerosols. Provide appropriate exhaust ventilation at places where dust is formed. For precautions see section 2.2. Conditions for safe storage, including any incompatibilities Store in cool place. Keep container tightly closed in a dry and well-ventilated place. Recommended storage temperature: -20 °C Light sensitive. Store under inert gas. Specific end use(s) Apart from the uses mentioned in section 1.2 no other specific uses are stipulated SECTION 8: Exposure controls/personal protection Control parameters Components with workplace control parameters Exposure controls Appropriate engineering controls Avoid contact with skin, eyes and clothing. Wash hands before breaks and immediately after handling the product. Personal protective equipment Eye/face protection Face shield and safety glasses Use equipment for eye protection tested and approved under appropriate government standards such as NIOSH (US) or EN 166(EU). Skin protection Handle with gloves. Gloves must be inspected prior to use. Use proper glove removal technique (without touching glove's outer surface) to avoid skin contact with this product. Dispose of contaminated gloves after use in accordance with applicable laws and good laboratory practices. Wash and dry hands. The selected protective gloves have to satisfy the specifications of EU Directive 89/686/EEC and the standard EN 374 derived from it. Full contact Material: Nitrile rubber Minimum layer thickness: 0,11 mm Break through time: 480 min Material tested:Dermatril® (KCL 740 / Z677272, Size M) Splash contact Material: Nitrile rubber Minimum layer thickness: 0,11 mm Break through time: 480 min Material tested:Dermatril® (KCL 740 / Z677272, Size M) data source: KCL GmbH, D-36124 Eichenzell, phone +49 (0)6659 87300, test method: EN374 If used in solution, or mixed with other substances, and under conditions which differ from EN 374, contact the supplier of the CE approved gloves. This recommendation is advisory only and must be evaluated by an industrial hygienist and safety officer familiar with the specific situation of anticipated use by our customers. It should not be construed as offering an approval for any specific use scenario. Body Protection Complete suit protecting against chemicals, The type of protective equipment must be selected according to the concentration and amount of the dangerous substance at the specific workplace. Respiratory protection Where risk assessment shows air-purifying respirators are appropriate use a full-face particle respirator type N100 (US) or type P3 (EN 143) respirator cartridges as a backup to engineering controls. If the respirator is the sole means of protection, use a full-face supplied air respirator. Use respirators and components tested and approved under appropriate government standards such as NIOSH (US) or CEN (EU). Control of environmental exposure Prevent further leakage or spillage if safe to do so. Do not let product enter drains. SECTION 9: Physical and chemical properties Information on basic physical and chemical properties a) AppearanceForm: solid b) Odourno data available c) Odour Thresholdno data available d) pHno data available e) Melting point/freezingno data available point f) Initial boiling point and no data available boiling range g) Flash pointno data available h) Evapouration rateno data available i) Flammability (solid, gas) no data available j) Upper/lowerno data available flammability or explosive limits k) Vapour pressureno data available l) Vapour densityno data available m) Relative densityno data available n) Water solubilityinsoluble o) Partition coefficient: n- log Pow: 9,4 octanol/water p) Auto-ignitionno data available temperature q) Decompositionno data available temperature r) Viscosityno data available s) Explosive propertiesno data available t) Oxidizing propertiesno data available Other safety information no data available SECTION 10: Stability and reactivity Reactivity no data available Chemical stability Stable under recommended storage conditions. Possibility of hazardous reactions no data available Conditions to avoid no data available Incompatible materials Strong oxidizing agents, Acid chlorides, Acid anhydrides Hazardous decomposition products Other decomposition products - no data available In the event of fire: see section 5 SECTION 11: Toxicological information Information on toxicological effects Acute toxicity LD50 Oral - rat - 35 - 47 mg/kg LD50 Oral - rat - 42 mg/kg LC50 Inhalation - rat - 4 h - 130 - 380 ppm LD50 Dermal - rat - 61 mg/kg Skin corrosion/irritation no data available Serious eye damage/eye irritation no data available Respiratory or skin sensitisation no data available Germ cell mutagenicity no data available Carcinogenicity IARC:No component of this product present at levels greater than or equal to 0.1% is identified as probable, possible or confirmed human carcinogen by IARC. Reproductive toxicity 25-HYDROXYCHOLECALCIFEROL is a analog of Vitamin D and may affect fetal development. Medical studies indicate an "increased rate of fetal abnormalities" as a result of high doses of Vitamin D given during pregancy. Overexposure may cause reproductive disorder(s) based on tests with laboratory animals. Specific target organ toxicity - single exposure no data available Specific target organ toxicity - repeated exposure no data available Ingestion - Causes damage to organs through prolonged or repeated exposure. Aspiration hazard no data available Additional Information RTECS: Not available Nausea, Vomiting, Diarrhoea, Headache, Dizziness, Weakness, To the best of our knowledge, the chemical, physical, and toxicological properties have not been thoroughly investigated. SECTION 12: Ecological information Toxicity no data available Persistence and degradability no data available Bioaccumulative potential no data available Mobility in soil no data available Results of PBT and vPvB assessment PBT/vPvB assessment not available as chemical safety assessment not required/not conducted Other adverse effects no data available SECTION 13: Disposal considerations Waste treatment methods Product Offer surplus and non-recyclable solutions to a licensed disposal company. Dissolve or mix the material with a combustible solvent and burn in a chemical incinerator equipped with an afterburner and scrubber. Contaminated packaging Dispose of as unused product. SECTION 14: Transport information UN number ADR/RID: 2811IMDG: 2811IATA: 2811 UN proper shipping name ADR/RID: TOXIC SOLID, ORGANIC, N.O.S. (25-Hydroxyvitamin D3 monohydrate) IMDG: TOXIC SOLID, ORGANIC, N.O.S. (25-Hydroxyvitamin D3 monohydrate) IATA:Toxic solid, organic, n.o.s. (25-Hydroxyvitamin D3 monohydrate) Transport hazard class(es) ADR/RID: 6.1IMDG: 6.1IATA: 6.1 Packaging group ADR/RID: IIIMDG: IIIATA: II Environmental hazards ADR/RID: noIMDG Marine pollutant: noIATA: no Special precautions for user no data available SECTION 15 - REGULATORY INFORMATION N/A SECTION 16 - ADDITIONAL INFORMATION N/A

安全

• 符号: GHS02, GHS07
• 信号词: Danger
• 危害声明: H225-H319
• 警示性声明: P210-P280-P305 + P351 + P338-P337 + P313-P403 + P235
• 个人防护装备: Eyeshields;Faceshields;full-face particle respirator type N100 (US);Gloves;respirator cartridge type N100 (US);type P1 (EN143) respirator filter;type P3 (EN 143) respirator cartridges
• 危害码 (欧洲): T+:Very toxic
• 风险声明 (欧洲): R28
• 安全声明 (欧洲): 28-36/37-45
• 危险品运输编码: UN 2811 6.1/PG 2
• WGK德国: 3